by kati.sallinen@desentum.fi | Sep 14, 2026 | News
A scientific paper reporting the Phase 1 clinical trial results of DM-101PX has been published in the renowned journal Clinical & Experimental Allergy by Desentum together with clinical and academic collaborators. The randomised, placebo-controlled trial tested a...
by kati.sallinen@desentum.fi | Jun 9, 2026 | News
Two abstracts related to Desentum’s product development projects have been accepted for presentation at the annual congress of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Türkiye, on Jun 12–15, 2026. The abstracts focus on...
by kati.sallinen@desentum.fi | Apr 27, 2026 | News
Desentum’s 18 M€ share issue organised by the Finnish growth equity company Springvest marks the largest public share issue* ever conducted in Finland by an unlisted growth company. The company is advancing a novel allergen immunotherapy platform that has the...
by kati.sallinen@desentum.fi | Feb 18, 2026 | News
A scientific paper about the mechanism of peanut allergy has been published in the renowned journal Allergy by the research group of the University of Eastern Finland and Desentum. The main peanut allergen Ara h 2 was crystallized together with an IgE antibody Fab...
by kati.sallinen@desentum.fi | Jan 21, 2026 | News
Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, today announced that its Phase 2 clinical study evaluating DM‑101PX for the treatment of birch pollen allergy has completed enrolment. 97 participants have been randomised...
by kati.sallinen@desentum.fi | Dec 2, 2025 | News
Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, announced today that the first trial participants have received their first doses in a Phase 2 clinical study, BASIT, evaluating DM-101PX for treatment of birch pollen allergy....
